CymaBay Therapeutics (CBAY) Receiving Somewhat Favorable Media Coverage, Report Finds

Galtero Lara
Abril 11, 2018

The stock's short float is around of 4.72% and short ratio is 2.42. The major pharmaceuticals company reported $10.55 million value for the 2017Q4.

The stock increased 0.52% or $0.05 during the last trading session, reaching $9.7. A total of 7,627,241 shares exchanged hands during the intra-day trade contrast with its average trading volume of 1.08M shares, while its relative volume stands at 17.25.

News headlines about CymaBay Therapeutics (NASDAQ:CBAY) have been trending somewhat positive recently, according to Accern Sentiment. CBAY's SI was 2.06M shares in April as released by FINRA. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company's stock worth $251,000 after purchasing an additional 12,300 shares during the last quarter. Currently, the 14-day ADX for Cymabay Therapeutics (CBAY) is 33.03. Cymabay Therapeutics (NASDAQ:CBAY)'s price to sales ratio for trailing twelve month stands at 67.88, whereas its price to book ratio for the most recent quarters is at 6.25.

Traders have different rules for what constitutes liquidity and a good guide is the volume of trades and volume of shares that are traded each day.

COPYRIGHT VIOLATION NOTICE: "CymaBay Therapeutics (CBAY) Earns Buy Rating from Piper Jaffray" was reported by The Lincolnian Online and is the property of of The Lincolnian Online.

3/28/2018-HC Wainwright initiated coverage with a Buy rating. Cedar Fair had 25 analyst reports since August 24, 2015 according to SRatingsIntel. The company was initiated on Wednesday, September 16 by Janney Capital. Finally, Zacks Investment Research downgraded shares of CymaBay Therapeutics from a hold rating to a sell rating in a report on Tuesday, January 16th.

More news: Commonwealth Games: Jack Laugher holds nerve to win springboard gold

NASDAQ CBAY traded up $0.59 during trading hours on Friday, hitting $12.07. On Thursday, February 18 the stock rating was maintained by FBR Capital with "Outperform".

In related news, Director Kurt Von Emster sold 138,253 shares of the firm's stock in a transaction that occurred on Monday, January 22nd. The firm has "Buy" rating given on Monday, February 26 by Keefe Bruyette & Woods. (NYSE:NEE) to report earnings on April, 20. They expect $1.29 earnings per share, up 12.17% or $0.14 from last year's $1.15 per share. Now the institutional investor is holding 1.15 million shares, compared to the 1.54 million from the previous quarter.

CymaBay Therapeutics (NASDAQ:CBAY)'s stock had its "outperform" rating restated by Leerink Swann in a research report issued to clients and investors on Wednesday, The Fly reports. Therefore 100% are positive. Cymabay Therapeutics Inc has $27.0 highest and $2.25 lowest target. Oppenheimer set a $15.00 price objective on CymaBay Therapeutics and gave the company a buy rating in a report on Wednesday, January 10th.

Cymabay Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. On Wednesday, March 28 the rating was maintained by Leerink Swann with "Buy". Research analysts often publish stock price targets along with buy-sell recommendations. The firm has "Buy" rating given on Friday, July 1 by Roth Capital. In Thursday, March 15 report Piper Jaffray maintained it with "Buy" rating and $16.0 target.

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The stock has a market capitalization of $678.82 Million however its outstanding shares are 56.24 Million. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout.

The price-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings.

Otros informes por

Discuta este artículo